Regeneron Q2 revenues up 11% to $3.16B; EPS $8.50 GAAP/$10.24 non-GAAP

REGENERON PHARMACEUTICALS, INC.

2023-Q2 EPS reported $15.68 revenue$6,320,200,000

Q2 2023 total revenues $3.158B (+11% YoY); GAAP diluted EPS $8.50 (up 14%); non-GAAP diluted EPS $10.24 (up 5%).
Dupixent global net sales (Sanofi) rose 33% to $2.79B; EYLEA US net sales fell 7% to $1.50B on lower pricing/competition.
FDA issued CRL for aflibercept 8 mg due to contract manufacturer issues; expects FDA action on BLA in Q3 2023.
Repurchased $723M in shares during Q2; $2.3B remained under buyback program as of June 30, 2023.
Updated 2023 guidance: GAAP R&D $4.315-4.455B; non-GAAP R&D $3.825-3.925B; SG&A and gross margin ranges unchanged.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

REGENERON PHARMACEUTICALS, INC. reported the quarter ended June 30, 2023 results: revenue $3.16 billion, EPS $8.50.

Period: the quarter ended June 30, 2023
Revenue: $3.16 billion
EPS: $8.50
Result: reported results

Exact text from the filing

EXHIBIT 99.1 Document Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2023 Financial and Operating Results • Second quarter 2023 revenues increased 11% to $3.16 billion versus second quarter 2022 • Second quarter 2023 Dupixent ® global net sales (recorded by Sanofi) increased 33% to $2.79 billion versus second quarter 2022 • Second quarter 2023

View on SEC.gov

Browse all earnings releases →

REGENERON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001804220-23-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.